All In Biotech

Drug Trial Radar · NCT07038876

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Orally Administered ML-007C-MA in Inpatient Adult Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

307

Actual

Start

Jun 27, 2025

Primary completion

Jun 4, 2026

Study completion Jun 11, 2026

Sponsor

Lead sponsor
MapLight TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.

Conditions

  • Schizophrenia

Interventions

  • PlaceboDrug

    Matched Placebo

  • ML-007C-MA BIDDrug

    ML-007C-MA dosed as 210/3 mg BID

  • ML-007C-MA QDDrug

    ML-007C-MA dosed as 330/6 mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: Baseline and End of Treatment (5 weeks)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Little Rock, Arkansas

  • Clinical Site

    Bellflower, California

  • Clinical Site

    Culver City, California

  • Clinical Site

    Garden Grove, California

  • Clinical Site

    Lemon Grove, California

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Montclair, California

  • Clinical Site

    Orange, California

  • Clinical Site

    Riverside, California

  • Clinical Site

    San Diego, California

  • Clinical Site

    Sherman Oaks, California

  • Clinical Site

    Torrance, California

  • Clinical Site

    Hollywood, Florida

  • Clinical Site

    Miami Lakes, Florida

  • Clinical Site

    West Palm Beach, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Decatur, Georgia

  • Clinical Site

    Chicago, Illinois

  • Clinical Site

    Marlton, New Jersey

  • Clinical Site

    Staten Island, New York

  • Clinical Site

    North Canton, Ohio

  • Clinical Site

    Austin, Texas

  • Clinical Site

    DeSoto, Texas

  • Clinical Site

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.